A rapid, simple and highly sensitive UPLC-MS/MS method for quantitation of pimavanserin in plasma and tissues: Application to pharmacokinetics and brain uptake studies in mice

Discovery of pyridazinone derivatives bearing tetrahydroimidazo[1,2-a]pyrazine scaffold as potent inhibitors of transient receptor potential canonical 5 to ameliorate hypertension-induced renal injury in rats

Transient receptor potential canonical 5 (TRPC5) is a calcium-permeable non-selective cation channel involved in various pathophysiological processes, including renal injury. Recently, GFB-887, an investigational pyridazinone TRPC5 inhibitor, demonstrated significant therapeutic potential in a Phase II clinical trial for focal segmental glomerulosclerosis (FSGS), a rare and severe form of chronic kidney disease (CKD). In the current study, based on the structure of GFB-887, we conducted extensive structural modification to explore novel TRPC5 inhibitors with desirable drug-like properties and robust nephroprotective efficacy. A series of pyridazinone derivatives featuring a novel tetrahydroimidazo[1,2-a]pyrazine scaffold were synthesized and their activities were evaluated in HEK-293 cells stably expressing TRPC5 using a fluorescence-based Ca2+ mobilization assay. Among these compounds, compound 12 is turned out to be a potent TRPC5 inhibitor with apparent affinity comparable to the parent compound GBF-887. Compound 12 is highly selective on TRPC4/5 over TRPC3/6/7 and hERG channels, along with acceptable pharmacokinetic properties and a favorable safety profile. More importantly, in a rat model of hypertension-induced renal injury, oral administration of compound 12 (10 mg/kg, BID) efficaciously reduced mean blood pressure, inhibited proteinuria, and protected podocyte damage. These findings further confirmed the potential of TRPC5 inhibitors on the CKD treatment and provided compound 12 to be a valuable tool for exploring TRPC4/5 pathophysiology.

Accurate Quantification of Nervous System Drugs in Aqueous Samples at Trace Levels by Binary Solvent Dispersive Liquid-Liquid Microextraction-Gas Chromatography Mass Spectrometry

Pharmaceutical products are widely consumed globally and are commonly found in wastewaters as a result of constant excretion and disposal into sewers. The present study proposes an efficient binary solvent dispersive liquid-liquid microextraction (BS-DLLME) method that was developed for preconcentration of 7 nervous system drug active compounds from aqueous media for their determination at trace levels by gas chromatography-mass spectrometry. The drug analytes included 3 antidepressants, 2 antipsychotics, 1 antiepileptic, and 1 antidementia. Optimum conditions of the BS-DLLME method were acquired by univariate optimization of parameters including type of binary solvents, ratio of binary solvents, type of disperser solvent, volume of binary solvents, and volume of disperser solvent. Detection and quantification limits were calculated in the range of 0.28 to 6.5 µg/L. Municipal wastewater, medical wastewater, synthetic domestic wastewater, and lake water were utilized as real samples in spike recovery experiments; and the results (94-106%) indicated the method's applicability and accuracy at quantifying the analytes in complex matrices. Environ Toxicol Chem 2021;40:1570-1575. © 2021 SETAC.

A UPLC-MS/MS method for simultaneous determination of nine antiepileptic drugs in human plasma and its application in TDM

With the purpose of carrying out therapeutic drug monitoring (TDM) of nine antiepileptic drugs simultaneously in the clinic, a UPLC-MS/MS assay method was developed and validated. Separation of antiepileptic drugs and internal standard (naproxen and diazepam) was performed on an Agilent Eclipse XDB-C₁₈ column (50.0 × 2.1 mm, 1.7 μm) using water and acetonitrile as mobile phase for gradient elution. Polarity switch ionization mode (positive-negative-positive) was performed in a total run time of 3.0 min. The method validation was conducted based on bioanalytical method validation guidance, including specificity, calibration curve, precision, accuracy, recovery, matrix effect, stability and dilution integrity, and all of the results satisfied the requirements. Consequently, the proposed method was applied to the TDM of nine antiepileptic drugs and was proved to be sensitive, reliable and specific to determine antiepileptic drugs in human plasma simultaneously. Meanwhile, the TDM results showed that the plasma drug concentration of many patients was not within the effective therapeutic range, especially those taking topiramate, oxcarbazepine and levetiracetam, which was of great guiding significance to rational drug use and timely adjustment of the treatment plan. Therefore, individualized therapy based on advanced analytical methods and TDM theory is of great practical significance.